To be the leading cGMP CDMO globally in adherent bioprocessing/ continuous processing using flow chemistry utilizing our own in house proprietary/patented platforms and accelerate the discovery to delivery process of vaccines (human, animal, cancer), oncolytic viruses, cell/gene therapy, tissue engineering, mabs/recombinant proteins, diagnostics, small molecules, cosmeceuticals, peptides, biopolymers, bioscaffolds, and cosmetics/fast-moving consumer goods (FMCG).
We focus on offering vaccine-, bio-, cell- and gene-therapy development manufacturing services using primarily its proprietary Adherent Tide Motion Platform supplemented by single-use suspension and fermentation, downstream bioprocessing, and custom bioengineering equipment for client specific therapeutics.
Within the in vitro/in vivo Diagnostic space, we focus on developing mAb-based antigens, single-domain antibodies for radio imaging, RT PCR reagents, RCL diagnostics. We work with collaborators to provide turnkey mobile Dx labs: Aster Xpress™.
Within the chem- biopolymer- cosmetic, personal care, cosmeceutical segments, we excel in converting batch processes into continuous flow chemistry, closed aseptic processing within isolators and variety of skin safety/efficacy testing services.
For the COVID-19 pandemic we are working on an end-to-end trace, test, and treat platform from swab booths, to mobile labs, turnkey modular screening and treatment centres with isolation rooms as well as working on diagnostics, therapeutics, and vaccines.
We are driven to provide One Health-based measures, geared towards vaccination and less antibiotic dependence, to ensure animals considered as companions and nourishment providers, are free from diseases that transcends human and environmental health systems.
Esco was founded in Singapore and began to pioneer cleanroom technology in Souteast Asia
Esco expands distribution to pharmaceutical life science biotech and medical research markets
Esco earns first EN 12469 cert. for BSC
Esco earns onsite UL accreditation
Expansion of Esco life science and medical products
Esco VacciXcell was introduced
Esco Aster was introduced (first CDMO company in Asia utilizing its own proprietry Tide Motion technology)
Esco Aster and Institue of Molecular Cell Biology announce a collaboration to accelerate pre-clinical development of a hand foot and mouth vaccine.
Esco Aster and Bioprocessing Institute sign a Memorandum of Understanding to innovate on continuous manufacturing platform.
Esco Aster and National University of Singapore announce a development of single-use bioreactor-based stem cells for bone regeneration.
Esco Aster continues to grow with the outfitting of a cGMP-compliant PD,GLP, Phase 1 and 2 clinical trial facility.
XL Lin founded and manages the Esco Aster and Esco Healthcare Division within the Esco Lifesciences Group in 2009 developing the companies' very first cGMP downflow/containment booths and isolation systems from concept development to sales, project management, site-work, and validation.
Under his leadership, Esco Pharma has expanded from just a small division to now having 3 factories globally in USA/UK and Singapore. He brings his unique skillset in social entrepreneurship, market development, strategic product development, globally alliance networking, sales/contract management, clean air/containment facility, and systems design/integration into Esco VacciXcell. XL Lin graduated with a Bachelor of Sciences from University of Sydney and he is currently pursuing various options for further studies.